ArticleJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology2022
Outcomes of patients with moderate-to-severe Ischemia excluded from the ischemia trial.
Article in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Automated AI-Based Aortic Measurements From Attenuation Correction CT as an Adjunctive Cardiovascular Risk Biomarker: An International Multicenter Study.Circulation. Cardiovascular imaging · 2026Article
- Eligibility of real-world patients for aspirin primary prevention trials in cardiovascular disease.BMC medicine · 2026Article
- AI-based identification of patients who benefit from revascularization: a multicenter study.medRxiv : the preprint server for health sciences · 2025Article
- The Relationship Between Quantitative Ischemia, Early Revascularization, and Major Adverse Cardiovascular Events: A Multicenter Study.JACC. Advances · 2025Article
- Reassessing the Role of Ischemia Imaging: Insights from the ISCHEMIA Trial.Nuclear medicine and molecular imaging · 2024Review
- Association between an Early Revascularization Strategy and Major Cardiac Events Based on Left Ventricular Dyssynchrony in Patients at Intermediate Risk of Major Cardiac Events Using the J-ACCESS Risk Model.Internal medicine (Tokyo, Japan) · 2024Article
- Developing a framework for evaluating and comparing risk models.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Is your ischemic patient an ISCHEMIA patient?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Is SPECT myocardial perfusion imaging on its dying bed?Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Debate. "Orbiting" around the management of stable angina. The interventional cardiologist's perspective.REC, interventional cardiologyArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial showed no difference in outcomes between medical therapy vs coronary revascularization in the management of patients with stable coronary artery disease. We aimed to determine the percentage of patients with at least moderate ischemia that would have been eligible for enrollment and evaluate the outcomes of those who would not.
methodsConsecutive patients who underwent cardiac single-photon emission computed tomography (SPECT) between April 2016 and September 2019 were identified and all-cause mortality was determined.
resultsThere were a total of 1508 patients (mean age 67 ± 11.6 years, 69.5% males) with any perfusion defect on SPECT. Patients had a high prevalence of cardiac risk factors (73.4% with hypertension and 54.4% with diabetes mellitus.) Nearly half (709, 47%) had moderate-to-severe ischemia but over two-thirds (479/709, 66.3%) had at least one ISCHEMIA trial exclusion criteria. Patients meeting ISCHEMIA enrollment criteria had a significantly lower all-cause mortality than those who would have been excluded (3.91% vs. 11.3%, respectively, P < .001).
conclusionOur results show that ISCHEMIA selected a relatively small subset of lower risk patients among the larger higher risk group of patients with moderate-to-severe ischemia typical to most cardiology centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.